Prostasin has long interested researchers because of its association with preeclampsia, a gestational hypertension disorder that disrupts the blood supply of the placenta and endangers both mother and fetus. In mice, complete deficiency of Prss8 is lethal by embryonic day 14.5, and the embryos show impaired maturation of the placental labyrinth, the intricate vascular interface where maternal and fetal circulations exchange oxygen and nutrients. What remained unclear was whether the protease acts directly within blood-forming tissues or whether its effects on blood cells are secondary to the failing placenta. The new study, led by Sara Di Carlo, Adrian Salas-Bastos, Olaia Naveiras and Edith Hummler among others, set out to answer that question with a combination of classical developmental biology and single-cell genomics.

The team examined Prss8-deficient embryos at embryonic days 11.5 and 12.5, a critical window when the embryo transitions from relying on primitive red blood cells made in the yolk sac to producing definitive blood lineages that will sustain it for life. At both time points, they found a reduced frequency of circulating primitive erythroid cells and of definitive erythroblasts derived from erythro-myeloid progenitors in three key hematopoietic sites: the yolk sac, the placenta and the fetal liver. This was not a subtle shift. Across the entire network of embryonic blood production, the absence of prostasin thinned out the population of maturing red cells, suggesting the protease supports erythropoiesis at a systemic level rather than in a single niche.

To understand what was going wrong inside the affected cells, the researchers turned to single-cell RNA sequencing, a technique that profiles the gene expression of individual cells and can reveal developmental states that bulk measurements average away. The analysis of primitive erythroid cells from Prss8-deficient embryos revealed two striking transcriptional signatures. First, genes encoding fetal hemoglobin, the oxygen-carrying molecules that primitive red cells depend on, were downregulated. Second, ribosomal genes were upregulated, hinting at an altered translational program or a stress response within the cells. Together, these changes indicate a defective erythroid maturation: the red blood cell precursors were not simply fewer in number, they were failing to progress along their normal differentiation trajectory.

One of the most consequential observations came from asking where prostasin itself is expressed during this process. The answer, according to the study, is nowhere near the cells that need it. Prostasin expression was absent in circulating erythroid cells, which means the protease cannot be acting cell-intrinsically within the red cell lineage. The researchers therefore propose that prostasin regulates primitive erythropoiesis in a cell-extrinsic manner, shaping the environment in which red cells mature rather than the cells themselves. This distinction matters enormously for how the finding is interpreted: prostasin is not a blood cell gene, but a gene whose product in surrounding tissues makes blood cell development possible.

The search for that extrinsic environment led the team to the vasculature. In Prss8-deficient embryos, yolk sac vascular remodeling was impaired, as evidenced by reduced vessel branching and reduced junctions between vessels. The yolk sac is the first hematopoietic and vascular organ of the embryo, and its blood vessels must remodel and expand in lockstep with the growing demand for oxygen transport. When branching fails, the circulatory architecture that delivers oxygen and removes waste is compromised. The authors suggest that this vascular defect likely affects placental vascularization as well, compounding the labyrinth maturation failure already known from earlier work, and contributing to the embryonic demise observed by day 14.5.

This vascular connection is where the study becomes most relevant to human pregnancy. Preeclampsia is fundamentally a disorder of placental blood supply, characterized by inadequate remodeling of maternal spiral arteries and subsequent placental ischemia. The new data show that in mice, loss of prostasin simultaneously disrupts embryonic red cell production and vascular patterning in the yolk sac and placenta. The convergence of these two processes, hematopoiesis and vascular development, in a single protease suggests that Prss8 dysregulation may contribute to placental pathologies through mechanisms that go beyond the classical view of preeclampsia as purely a maternal vascular disorder. A failing fetal blood system and a failing placental circulation may be two faces of the same underlying defect.

Technically, the study’s strength lies in its multi-scale approach. By combining embryo staging at defined gestational days, flow-based quantification of erythroid populations across three organs, and single-cell transcriptomics, the researchers could distinguish between a loss of cells and a loss of maturation within the cells that remain. The downregulation of fetal hemoglobin genes is particularly telling, because primitive erythroid cells are defined by their robust hemoglobin production; a primitive cell that fails to express hemoglobin genes is a cell that has lost its identity. The concurrent upregulation of ribosomal genes may reflect a compensatory attempt to sustain protein synthesis, or an early sign of cellular stress, and disentangling these possibilities will be an important direction for future work.

The cell-extrinsic mechanism also reframes what prostasin does biologically. As a membrane-bound serine protease, prostasin is known to participate in epithelial sodium channel regulation and in the proteolytic processing of extracellular substrates. Its absence from circulating erythroid cells implies that its relevant substrates lie in the vascular and stromal compartments of the yolk sac, placenta and fetal liver. Whether prostasin processes a specific extracellular molecule that signals to erythroid precursors, or whether its vascular effects alone account for the erythroid defects, remains an open question that the study raises but does not fully resolve. The impaired vessel branching and junctions provide a plausible route: a poorly patterned vasculature cannot properly support the niches in which red cells are born and mature.

For now, the findings unveil a novel role for prostasin during developmental erythropoiesis and vascular patterning, and they provide insight into how Prss8 dysregulation may contribute to placental pathologies such as preeclampsia. The work demonstrates that a protease associated with a pregnancy disorder in humans is essential for the embryonic blood system in mice, linking placental health, vascular architecture and red cell maturation in a single genetic axis. As researchers pursue the extracellular substrates and signaling pathways through which prostasin acts, the study opens a path toward understanding whether the same protease that sculpts the embryonic vasculature also safeguards the placental circulation that sustains human pregnancies, and whether its dysregulation could one day be targeted therapeutically in disorders of the placenta.

Subject of Research: The role of the serine protease prostasin in embryonic erythropoiesis and placental vascular development

Article Title: Impaired erythroid maturation in murine embryos upon loss of the preeclampsia-associated serine protease prostasin Prostasin loss impairs erythropoiesis

Article References: Di Carlo, S., Salas-Bastos, A., Castelblanco Castelblanco, M., Auberson, M., Wang, D., Rumpler, M., Tournier, M., Staub, O., Sommer, L., Ferreira Lopes, S., Jiménez Sànchez, A., Naveiras, O., & Hummler, E. (2026). Impaired erythroid maturation in murine embryos upon loss of the preeclampsia-associated serine protease prostasin Prostasin loss impairs erythropoiesis. PLOS One, 21(10), e0360958. https://doi.org/10.1371/journal.pone.0360958

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360958

Keywords: prostasin, Prss8, preeclampsia, erythropoiesis, erythroid maturation, yolk sac, placenta, fetal hemoglobin, single-cell RNA sequencing, vascular remodeling, embryonic development, serine protease

To understand why the new therapies matter, it helps to grasp the underlying biology. Beta-thalassemia arises from mutations that reduce or eliminate production of the beta-globin chain, one of the two protein components of adult hemoglobin, the molecule that ferries oxygen through the bloodstream. Without adequate beta-globin, red blood cells are fragile and inefficient, producing the severe anemia that defines the major form of the disease. For decades the standard of care has been regular blood transfusions to top up functional hemoglobin, combined with iron chelation therapy to remove the iron that each transfusion deposits in vital organs. These measures have dramatically extended survival; long-term cohort studies now document patients with beta-thalassemia major living more than fifty years after diagnosis. Yet the treatment burden is enormous, the costs are high, and complications ranging from iron-overload cardiomyopathy to endocrine damage persist even in well-managed patients.

The first curative strategy, and still the only one with decades of accumulated evidence, is allogeneic hematopoietic stem cell transplantation, or HSCT. The logic is elegant: replace the patient’s faulty blood-forming system with healthy stem cells from a matched donor, and the regenerated blood system will produce normal hemoglobin for life. Registry data from the European Society for Blood and Bone Marrow Transplantation and long-running national programs in France and elsewhere demonstrate that transplantation from matched sibling donors can produce durable, transfusion-free lives, with studies describing a genuine return to normal life for successfully transplanted patients. Programs in developing countries, including Pakistan, have shown that the procedure can deliver cures even in resource-constrained settings.

But HSCT carries serious constraints that the review highlights in detail. Suitable donors are scarce, since only a minority of patients have an HLA-matched sibling, and the odds of finding a matched family donor vary widely across populations. The procedure itself requires myeloablative conditioning, a chemotherapy regimen that wipes out the patient’s existing bone marrow, exposing them to risks of graft rejection, graft-versus-host disease, and long-term late effects. Research on children and adolescents transplanted for non-malignant disorders documents lasting consequences that complicate the risk-benefit calculation for a disease that transfusion therapy can manage, imperfectly but chronically. Haploidentical transplantation, using partially matched family donors with novel conditioning regimens, is expanding the donor pool, yet the fundamental hazards remain.

Enter gene therapy, which sidesteps the donor problem entirely by engineering the patient’s own hematopoietic stem cells. The concept dates back to early retroviral transfer experiments in the 1990s, when researchers first showed that a normal beta-globin gene could be expressed in erythroid cells after viral transfer, and to mouse models demonstrating long-term expression of transferred human beta-globin. The technical breakthrough came with lentiviral vectors, engineered from HIV, which can carry the large and complex beta-globin gene locus into stem cells and deliver it stably into the genome. Systematic studies of lentiviral packaging established the capacity of these vectors, and preclinical evaluations of improved beta-globin vectors for beta-thalassemia and sickle cell disease demonstrated both efficacy and an integration profile that supported clinical translation.

The clinical payoff has been substantial. The Northstar-2 trial of lentiglobin gene therapy reported encouraging safety and efficacy in patients with transfusion-dependent beta-thalassemia and non-beta-zero/beta-zero genotypes, with many participants achieving lasting transfusion independence. Because the engineered cells are the patient’s own, there is no risk of graft-versus-host disease, a decisive advantage over allogeneic transplantation. Nonetheless, the review notes that safety monitoring continues: a case of myelodysplastic syndrome in a sickle cell patient treated with lentiviral gene therapy was found to be unrelated to the vector, but it underscores why long-term follow-up and integration-site analyses remain integral to the field. Insertional mutagenesis, however rare, is the theoretical shadow hanging over every gene-addition approach, and decades of vector-design refinement have been devoted to minimizing it.

The most dramatic recent development, and the centerpiece of the review’s forward-looking analysis, is CRISPR/Cas9 genome editing. Rather than adding a gene, editing reprograms the patient’s own genome at a precise location. The clinical star of this approach is exagamglogene autotemcel, known as exa-cel and marketed as Casgevy, which modifies the erythroid enhancer of the BCL11A gene. BCL11A is a transcription factor that silences fetal hemoglobin after birth; disrupting its enhancer in blood stem cells allows the fetal gamma-globin genes to reactivate, flooding red cells with fetal hemoglobin that functionally compensates for the defective adult beta-globin. The strategy builds on earlier zinc-finger nuclease work targeting the same enhancer, and on landmark clinical results showing that CRISPR-Cas9 editing could benefit patients with both sickle cell disease and beta-thalassemia. The review emphasizes that exa-cel has now demonstrated significant rates of sustained transfusion independence in eligible patients with transfusion-dependent beta-thalassemia, a milestone that turned a laboratory concept into an approved medicine.

The therapeutic landscape also includes less invasive adjuncts. Luspatercept, a fusion protein that binds transforming growth factor-beta family ligands, stimulates late-stage erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent patients, reducing transfusion burden without touching the genome. Meanwhile, systematic reviews of CRISPR applications in beta-thalassemia catalog a growing arsenal of editing strategies, from direct correction of patient-specific mutations to further enhancer manipulations. The review also points to genetic modifiers, such as co-inherited alpha-globin variants, that shape disease severity and could influence which patients benefit most from which intervention. Off-target effects of CRISPR editing remain an active area of scrutiny, though the enhancer-targeting strategy, which mimics naturally occurring benign variation rather than correcting a mutation, is considered inherently favorable for precision.

Despite the headline successes, the review is unflinching about the obstacles that stand between these therapies and the patients who need them most. Every autologous gene therapy and gene-editing product still requires myeloablative conditioning to make room in the bone marrow, exposing patients to transplant-grade toxicity without the donor-matching constraints but with equivalent chemotherapy burden. Manufacturing is complex: each patient’s stem cells must be harvested, engineered, quality-controlled, and reinfused, a bespoke process that cannot be scaled the way conventional drugs can. The result is a price tag that places exa-cel and lentiviral products far beyond the reach of most health systems. This is a bitter irony given the epidemiology: beta-thalassemia clusters in South Asia, the Middle East, and the Mediterranean, precisely the low- and middle-income regions where transfusion infrastructure is already strained and where the new cures are least affordable. Studies from Iran, Pakistan, and Bangladesh documenting knowledge gaps, chelator misuse, and the burden on families illustrate the scale of unmet need.

The authors’ conclusion is measured but transformative in its implication: beta-thalassemia care is shifting from lifelong supportive management toward potentially curative and transformative intervention, but the promise will remain unevenly distributed unless access expands. Long-term follow-up of the first edited patients is still in its early years, and durability over decades, the real test of any cure, has yet to be proven. The review calls for continued evaluation of long-term safety alongside serious efforts to drive down costs, simplify manufacturing, and build delivery capacity in the countries that carry the heaviest disease burden. Carrier screening programs, premarital counseling, and public awareness campaigns remain essential public-health complements, reducing new cases even as laboratory advances rewrite treatment. What was once a disease managed with someone else’s blood may, within a generation, be a disease rewritten in a patient’s own genome, provided the revolution in molecular medicine can cross the gap between wealthy clinics and the world’s thalassemia heartland.

Subject of Research: Curative strategies for beta-thalassemia, including stem cell transplantation, gene addition, and CRISPR genome editing

Article Title: Recent trends and innovative strategies in the curative approach for β-thalassemia: a current prospect and future perspective

Article References: Usmani, F., Ali, S. U., Ahad, F., & Saifullah (2026). Recent trends and innovative strategies in the curative approach for β-thalassemia: a current prospect and future perspective. Molecular Biology Reports, 53(1), Article 1703. https://doi.org/10.1007/s11033-026-12908-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12908-2

Keywords: beta-thalassemia, CRISPR/Cas9, gene therapy, hematopoietic stem cell transplantation, exagamglogene autotemcel, Casgevy, BCL11A, fetal hemoglobin, lentiviral vector, iron chelation, transfusion independence, hemoglobinopathy

The molecular story begins with structure. Human hemoglobin is a tetrameric protein that makes up roughly 96 percent of the dry weight of a red blood cell, and it comes in developmentally staged varieties. Fetal hemoglobin, or HbF, is built from two alpha-globin and two gamma-globin chains, giving it the designation alpha-2-gamma-2. Adult hemoglobin, HbA, swaps the gamma chains for beta chains, producing alpha-2-beta-2. The difference sounds trivial, a matter of two protein subunits, but it fundamentally alters the molecule’s biophysical behavior. HbF binds oxygen more avidly than HbA, a property that allows fetal red blood cells to snatch oxygen from maternal blood across the placenta and deliver it to developing tissues at precisely the right level, neither starving the fetus nor flooding it with excess oxygen.

What makes this system even more striking is that the switch from fetal to adult hemoglobin production runs on an internal developmental clock. It proceeds on schedule whether the fetus remains in the womb or arrives months early into a neonatal intensive care unit. At term birth, HbF typically constitutes 70 to 90 percent of total hemoglobin, with most of the remainder being HbA. In the weeks and months after birth, that balance steadily shifts as the bone marrow ramps up adult hemoglobin synthesis. But for infants born extremely preterm, this transition unfolds in the alien environment of the NICU, punctuated by blood draws, illness, and often repeated transfusions of adult donor blood, and until now clinicians have had no validated reference intervals to tell them what a normal HbF percentage should look like at any given gestational age.

That gap matters because a growing body of research has linked fetal hemoglobin levels to the outcomes that define preterm survival. Observational studies have associated a low fraction of HbF with bronchopulmonary dysplasia, the chronic lung disease of prematurity, and with retinopathy of prematurity, the disordered eye vessel growth that can threaten the vision of very preterm infants. A 2026 analysis further reported that the fetal hemoglobin fraction correlates with the risk of complications of prematurity more broadly. The logic is biologically plausible: fetal red cells carry oxygen with different kinetics and may behave differently in the microvasculature, so the composition of a preterm infant’s blood could influence how oxygen-sensitive organs develop. Yet without reference intervals, an individual laboratory value could not be confidently classified as normal or abnormal.

The Utah-led team attacked the problem with a statistical strategy that has quietly been transforming laboratory medicine. Rather than recruiting a pristine cohort of healthy volunteers, which is nearly impossible in neonatology, the researchers mined deidentified clinical records and applied the refineR algorithm, a computational method designed to extract reference intervals from real-world laboratory data. The algorithm works by identifying the apparently healthy portion of a mixed distribution, mathematically separating the central body of routine results from the pathological tail contributed by sick patients. The same team had previously used refineR to establish improved reference intervals for circulating nucleated red blood cell counts in neonates, and the approach sidesteps the selection biases that plague conventional reference interval studies.

To build the fetal hemoglobin intervals, the investigators focused on non-transfused infants spanning 23 to 40 weeks of gestation, deliberately excluding babies whose red cell populations had been altered by donor blood. This exclusion is critical, because a transfusion of adult blood instantly dilutes a preterm infant’s HbF fraction and would contaminate any attempt to define the natural developmental curve. The retrospective, deidentified records review was approved by the Intermountain Health Institutional Review Board and the University of Utah Institutional Review Board with a waiver of informed consent, and the work was conducted in compliance with federal human subjects regulations including HIPAA. Collaboration with neonatal intensive care medical directors at McKay-Dee Hospital and Utah Valley Hospital enabled collection of HbF values across the participating sites.

The resulting reference intervals, presented as curves across the gestational age spectrum from 23 to 40 weeks, give clinicians for the first time a population-based expectation for what percentage of hemoglobin should be fetal at each stage of preterm development. The clinical implications ripple outward in several directions. A HbF percentage falling below the expected interval might flag an infant at elevated risk for the oxygen-dependent complications of prematurity, prompting intensified surveillance of the lungs or retina. Conversely, the intervals provide an essential denominator for the growing interest in fetal red cell-based therapies, including a multicenter Italian randomized trial now testing cord red blood cell transfusions for severe retinopathy in preterm neonates. Interpreting any such intervention requires knowing where the natural baseline lies.

The study also highlights how much diagnostic power is locked inside routine laboratory measurements that hospitals already collect. Modern blood gas analyzers and automated hematology instruments can quantify hemoglobin derivatives and fractions at the push of a button, generating streams of data that historically were used only for individual patient decisions. Computational tools like refineR convert that accumulated clinical exhaust into population-level knowledge, a pattern now being repeated across neonatal hematology. For a field in which enrolling thousands of healthy newborns into reference studies is ethically and practically untenable, data-driven interval estimation may be the only realistic path forward, and the fetal hemoglobin curves are among its most consequential products to date.

There remain important caveats and next steps. Reference intervals describe populations, not prognoses, and the authors are careful to frame their curves as a foundation rather than a finished diagnostic test. Whether a low HbF fraction is a cause of bronchopulmonary dysplasia or retinopathy of prematurity, a marker of shared underlying vulnerability, or something in between, will require prospective studies that track infants against these new intervals over time. The investigators note that inquiries regarding data access can be addressed to the corresponding author, and the statistical code is available upon written request, inviting replication and extension by other centers. Still, the conceptual shift is hard to overstate: a molecule long celebrated for its role in the placental oxygen handshake now has a quantitative yardstick spanning the entire preterm period.

For the roughly one in ten infants born preterm worldwide, the stakes of oxygen management could hardly be higher, and fetal hemoglobin sits at the center of that physiology. By defining what normal looks like from 23 to 40 weeks of gestation, the Utah team has converted a century-old biological insight into a usable clinical benchmark. The next chapter, testing whether HbF percentage can stratify risk, guide transfusion strategy, or measure the benefit of fetal-cell therapies, now has the reference frame it needs. In the quiet arithmetic of reference intervals, neonatal medicine may have gained one of its most valuable new vital signs.

Subject of Research: Reference intervals for fetal hemoglobin percentage in preterm and term neonates from 23 to 40 weeks of gestation

Article Title: Establishing reference intervals for fetal hemoglobin percentage from 23 to 40 weeks of gestation using refineR

Article References: Zeiler, B. B., Bahr, T. M., Doyle, K., Maxfield, R. E., Stone, E. F., Addams, J. L., Ohls, R. K., & Christensen, R. D. (2026). Establishing reference intervals for fetal hemoglobin percentage from 23 to 40 weeks of gestation using refineR. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02918-0

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02918-0

Keywords: fetal hemoglobin, HbF, preterm infants, reference intervals, refineR algorithm, neonatology, neonatal intensive care, bronchopulmonary dysplasia, retinopathy of prematurity, oxygen transport, hemoglobin switching, transfusion medicine

Hydroxyurea has long been the cornerstone disease-modifying therapy for sickle cell anemia, the homozygous HbSS or HbSβ0-thalassemia genotypes that produce the most severe disease course. The drug works partly by reactivating fetal hemoglobin production, reducing the polymerization of sickle hemoglobin that drives red cell sickling, painful crises, and organ damage. Yet despite decades of clinical use, the precise relationship between dose and both clinical benefit and hematologic harm has remained uncertain, particularly across the diverse populations in which the disease is now treated.

To resolve this, the researchers conducted a systematic review and one-stage multilevel dose-response meta-analysis encompassing randomized trials, nonrandomized comparative studies, and longitudinal cohorts of children and adults with sickle cell disease. The quantitative synthesis focused principally on sickle cell anemia, with hydroxyurea dose expressed in mg/kg/day and achieved or maintenance doses preferred over starting doses. The primary benefit outcome was the rate of recurrent vaso-occlusive crises, while the primary safety outcomes were annual risks of severe or treatment-limiting neutropenia and thrombocytopenia, the two cytopenias that most often force dose reductions or discontinuation.

The modeling strategy was unusually rigorous. The team fitted Emax maximum-effect dose-response models as their primary analysis, testing linear and dose-independent alternatives in sensitivity analyses, and prespecified a decision rule requiring predicted annual neutropenia risk of no more than 5 percent and thrombocytopenia risk of no more than 3 percent, with at least an 80 percent simulation-derived probability that both criteria would be met simultaneously. Any eligible dose also had to retain near-optimal crisis control.

The results revealed a striking asymmetry between benefit and risk across the dose range. Empirical support for the primary analysis clustered between 20 and 28 mg/kg/day, and within that window recurrent vaso-occlusive crisis rates continued to fall, from a predicted 39.8 events per 100 person-years at 20 mg/kg/day to 32.5 at 28 mg/kg/day. Critically, the data showed no efficacy plateau: the Emax ED50 hit the upper limit of the prespecified search grid, and a simpler linear model actually fit marginally better, suggesting that whatever additional crisis reduction higher doses confer had not yet been exhausted within the observed range.

Safety told a different story. Predicted annual risk of severe or treatment-limiting neutropenia climbed steeply and early, from 1.98 percent at 20 mg/kg/day to 3.74 percent at just 21.5 mg/kg/day and 5.63 percent at 22.5 mg/kg/day. Thrombocytopenia, by contrast, remained uncommon and showed little dose dependence. Under the prespecified joint safety rule, the probability that both criteria were met was 87.1 percent at 20 mg/kg/day, 85.6 percent at 21 mg/kg/day, but only 77.8 percent at 21.5 mg/kg/day, failing the 80 percent threshold. The authors cautioned that because safety evidence was sparse and the joint classification depended partly on the relation between the two safety models, the low-20-mg/kg/day range should be read as an approximate safety transition rather than a precise toxicity threshold.

Within the empirically supported range, the lowest modeled recurrent crisis rate occurred at 28 mg/kg/day, and the unconstrained composite-benefit maximum at 25.5 mg/kg/day, but neither could clear the safety bar. Twenty-one mg/kg/day emerged as the highest dose satisfying the analytical rule, and the rounder conventional increment of 20 mg/kg/day was selected as the population reference dose, chosen from standard 2.5-mg/kg/day increments for practical prescribing.

The certainty of evidence behind these estimates was graded as very low for all three outcomes—recurrent crises, neutropenia, and thrombocytopenia—underscoring how much uncertainty remains. The review was prospectively registered with PROSPERO, and the authors emphasize that their decision framework, rather than any single trial, is what allows conflicting and sparse evidence to be converted into an actionable population-level recommendation.

Perhaps the most important clinical message is what the reference dose is not. The authors explicitly state that 20 mg/kg/day is neither a maximum tolerated dose nor a ceiling for treatment. Because crisis rates kept declining above 20 mg/kg/day, higher doses may well be appropriate for individual patients who need further clinical benefit, provided hematologic tolerance, adherence, and laboratory monitoring permit careful escalation. In resource-limited settings where laboratory surveillance is constrained, however, the population-level framework offers a defensible default that maximizes expected benefit while keeping predicted severe cytopenia risks within prespecified limits.

For the millions of people living with sickle cell anemia worldwide, most of them in sub-Saharan Africa, the findings translate decades of fragmented trial evidence into a single, transparent, quantitatively justified starting point for therapy—and a clear signal that the field still needs better safety data to push the benefit curve further.

Subject of Research: Dose-response relationship of hydroxyurea therapy in sickle cell anemia

Article Title: Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment

Article References: Paasi, G., Malaika, N., Ongodia, P., Amorut, D., & Olupot-Olupot, P. (2026). Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07679-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07679-5

Keywords: hydroxyurea, sickle cell anemia, dose-response meta-analysis, vaso-occlusive crisis, neutropenia, thrombocytopenia, benefit-risk assessment, systematic review, fetal hemoglobin, pediatric hematology, BMC Pediatrics, drug dosing

Hb F is the form of hemoglobin that dominates during fetal development. It consists of two alpha-globin chains and two gamma-globin chains, written as α2γ2. After birth, the body gradually replaces it with adult hemoglobin, α2β2, and in most healthy adults Hb F falls below 1 percent of total hemoglobin. In sickle cell disease, however, retaining more Hb F can be highly beneficial. The disease is caused by a mutation in the HBB gene that replaces the amino acid glutamic acid with valine in beta-globin, producing hemoglobin S. When oxygen levels fall, hemoglobin S molecules can stick together and form rigid polymers, distorting red blood cells into the characteristic sickle shape. Hb F interferes with this polymerization because gamma-globin-containing molecules do not participate in the same destructive assembly. Higher Hb F can therefore reduce red-cell rupture, blood-vessel blockage, severe pain and cumulative organ damage.

The review found that the strongest and most consistently replicated signals cluster in three genomic regions: BCL11A on chromosome 2, the intergenic region between HBS1L and MYB on chromosome 6, and the beta-globin gene cluster on chromosome 11, which includes the gamma-globin genes HBG1 and HBG2. BCL11A emerged as the most extensively studied locus, with 13 variants reported across 37 studies. Several of its variants, including rs1427407, rs4671393 and rs11886868, are located in an erythroid-specific enhancer, a regulatory DNA segment that controls gene activity in developing red blood cells. Hb F-increasing versions of these variants appear to weaken the enhancer’s ability to activate BCL11A. That matters because BCL11A normally acts as a powerful repressor of fetal hemoglobin after birth. When BCL11A levels decline, repression at the HBG1 and HBG2 promoters is eased, allowing gamma-globin production to persist.

The quantitative results reinforced the central role of the BCL11A enhancer, although they also exposed the difficulty of combining data from genetically diverse populations. Across nine studies, rs1427407 was associated with a pooled mean Hb F difference of 1.1, with a 95 percent confidence interval ranging from 0.287 to 1.914. The comparable pooled effects were 1.13 for rs4671393 and 1.229 for rs11886868, and all three reached statistical significance. Yet heterogeneity was very high, with I² values of 90.7, 95.2 and 87.9 percent, respectively. In meta-analysis, I² estimates the proportion of variation between studies that cannot be explained by sampling error alone. Such high values suggest that ancestry, local haplotypes, clinical characteristics, treatment exposure or differences in how Hb F was measured may substantially alter the effect of a variant. Some BCL11A variants even showed opposite associations in different populations, underscoring why a DNA change cannot always be interpreted in isolation from its surrounding genetic background.

The second major region, HBS1L-MYB, contained the largest number of reported variants: 28 across 25 studies. Many Hb F-increasing variants in this region appear to reduce expression of MYB, a regulator of red-cell development. Lower MYB activity can lengthen the cell cycle of erythroid progenitors, the immature cells that eventually become red blood cells. This extended developmental window may give gamma-globin expression more time to remain active, increasing the proportion of cells that contain Hb F. The variant rs4895441 produced one of the most consistent signals in the review, with a pooled mean difference of 0.356 and a 95 percent confidence interval of 0.181 to 0.532. Its I² value was 49.4 percent, considerably lower than for most of the other variants analyzed. By contrast, rs9399137 showed a directionally positive but statistically uncertain result, while rs28384513 produced a small suppressive effect that was remarkably consistent across five studies, with I² equal to zero.

The beta-globin cluster produced a particularly dramatic example of ancestry-dependent genetics. The HBG2 variant rs7482144, commonly known as the XmnI polymorphism, lies about 158 DNA letters upstream of the HBG2 gene promoter. Across 13 studies, it was associated with a pooled Hb F increase of 2.855, but the confidence interval was broad, from 0.626 to 5.083, and heterogeneity reached 96 percent. The variant’s effect depends heavily on the larger beta-globin haplotype in which it occurs. It is associated with especially high Hb F in the Arab-Indian haplotype, while its influence is weaker or nearly absent in some African populations carrying Bantu haplotypes. This genetic context helps explain why some individuals with sickle cell disease in parts of India and the Arabian Peninsula can have Hb F levels above 20 or even 30 percent, whereas many people of West African ancestry have much lower baseline levels. The difference is not simply a matter of one mutation, but of inherited regulatory combinations accumulated across the globin cluster.

The analysis also identified evidence for a wider network of biological influences beyond the three canonical regions. The most prominent was HMOX1, which encodes heme oxygenase-1, an enzyme involved in breaking down heme and responding to oxidative stress. The HMOX1 variant rs2071746 produced the largest pooled estimate among the variants included in the meta-analysis, with a mean difference of 4.453, but its I² value of 97.8 percent makes that number difficult to generalize. One possible mechanism is that increased heme oxygenase-1 activity generates carbon monoxide, which can activate soluble guanylate cyclase and raise cyclic GMP levels, a signaling pathway known to stimulate gamma-globin transcription. Other emerging genes included SIN3A, ZBTB7A, FOXO3, ANTXR1, BACH2 and HIF-1α. These genes touch several layers of regulation, including chromatin remodeling, transcriptional repression, oxygen sensing and erythroid stress responses. Most of these associations appeared in only one or two studies, so they are promising clues rather than established clinical markers.

The therapeutic implications are substantial because the genetic findings converge with modern efforts to reactivate fetal hemoglobin directly. BCL11A enhancer disruption is already being tested as a treatment strategy using CRISPR-Cas9 gene editing. By editing regulatory DNA in a patient’s blood-forming stem cells, researchers aim to reduce BCL11A activity specifically in red-cell precursors, releasing the brake on gamma-globin production. The review’s natural genetic associations provide an important biological validation of that approach: variants that weaken the same enhancer are linked to higher Hb F in people who have not undergone gene editing. The results could also support genotype-guided clinical trials. Patients carrying Hb F-promoting alleles might respond differently to hydroxyurea or other Hb F-inducing medicines than those carrying suppressive variants. However, the authors caution that no genetic test can yet replace clinical assessment. The evidence is uneven, effect sizes vary between populations, and many studies did not report results in a standardized form.

The review ultimately presents Hb F regulation as a multi-layered genetic network shaped by ancestry, haplotypes and interactions among regulatory proteins. It also highlights a serious equity problem: sub-Saharan Africa accounts for roughly 80 percent of the global sickle cell disease burden, yet African populations remain underrepresented in genomic research compared with African American, European and some Asian cohorts. The study’s authors argue that future work should prioritize large African genome-wide association studies, trans-ethnic fine-mapping and multi-omics analyses that connect DNA variants to chromatin accessibility and gene activity in erythroid cells. The current results are powerful because seven of the eight meta-analyzed variants showed directionally consistent associations, but they are not a universal genetic formula for sickle cell disease. Instead, they offer a framework for understanding why Hb F varies so widely between individuals—and a roadmap for developing treatments that could reproduce nature’s most effective protection against sickling.